MeiraGTx Announces Participation at Upcoming Investor Conferences
MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will speak at several key conferences in May 2021. The events include the BofA Securities 2021 Virtual Health Care Conference on May 12, the RBC Capital Markets Global Healthcare Conference on May 19, and Oppenheimer's Rare & Orphan Disease Summit on May 21. Live webcasts will be available on the Company’s Investors page. MeiraGTx focuses on gene therapies for inherited retinal diseases, neurodegenerative diseases, and severe xerostomia, with multiple programs in clinical development.
- None.
- None.
LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.
- BofA Securities 2021 Virtual Health Care Conference
Wednesday, May 12, 2021, 1:15 p.m. ET
- 2021 RBC Capital Markets Global Healthcare Conference
Wednesday, May 19, 2021, 4:50 p.m. ET
- Oppenheimer's Rare & Orphan Disease Summit
Friday, May 21, 2021 (1x1 meetings only)
Live webcasts of the presentations (where applicable) will be on the Investors page of the Company’s website at www.investors.meiragtx.com. For conferences that offer replays, presentations will be made available for a limited time.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.
Contacts
Investors:
MeiraGTx
Investors@meiragtx.com
or
Media:
Real Chemistry
Ben Rickles
(404) 502-6766
brickles@realchemistry.com
FAQ
When will MeiraGTx participate in the BofA Securities 2021 Virtual Health Care Conference?
What are the dates for MeiraGTx's conferences in May 2021?
How can I watch the MeiraGTx conference presentations?
What is the focus of MeiraGTx's clinical programs?
What is the stock symbol for MeiraGTx Holdings?
